References
- Antonopoulou I, Sapountzaki E, Rova U, Christakopoulos P. Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds. Comput Struct Biotechnol. 2022; 20:1306–1344.
- Katre SG, Asnani AJ, Pratyush K, Sakharkar NG, Bhope AG, Sawarkar KT, Nimbekar VS. Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro). Futur J Pharm Sci. (1)2022; 8:36.
- Zhu W, Shyr Z, Lo DC, Zheng W. Viral proteases as targets for coronavirus disease 2019 drug development. J Pharmacol Exp Ther. 2021; 378(2):166–172.
- Parmar M, Thumar R, Patel B, Athar M, Jha PC, Patel D. Structural differences in 3C-like protease (Mpro) from SARS-CoV and SARS-CoV-2: molecular insights revealed by molecular dynamics simulations. Struct Chem. 2022; 23:1–18.
- Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. (5626)2003; 300:1763–1767.
- Zhang W, Lin SX. Search of novel small molecule inhibitors for the main protease of SARS-CoV-2. Viruses. 2023;15(2):580.
- Kneller DW, Phillips G, O'Neill HM, Jedrzejczak R, Stols L, Langan P, Joachimiak A, Coates L, Kovalevsky A. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. Nat Commun. 2020; 11(1):3202.
- Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors. Science. 2020; 368(6489):409–412.
- Huang C, Shuai H, Qiao J, Hou Y, Zeng R, Xia A, Xie L, Fang Z, Li Y, Yoon C, et al. A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants. Signal Transduct Target Ther. 2023; 8:128.
- US Food and Drug Administration (FDA) [Internet]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. [last accessed 10 October 2023].
- US Food and Drug Administration (FDA) [Internet]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain. [last accessed 10 October 2023].
- US Food and Drug Administration (FDA) [Internet]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. [last accessed 10 October 2023].
- Ministry of Health, Labour and Welfare of Japan (MHW) [Internet]. Available from: https://www.mhlw.go.jp/stf/newpage_29320.html. [last accessed 10 October 2023].
- China National Medical Products Administration (NMPA) [Internet]. Available from: http://english.nmpa.gov.cn/2022-08/15/c_797867.htm. [last accessed 10 October 2023].
- Rut W, Groborz K, Zhang L, Sun X, Zmudzinski M, Pawlik B, Młynarski W, Hilgenfeld R, Drag M. Substrate specificity profiling of SARS-CoV-2 main protease enables design of activity-based probes for patient-sample imaging. BioRxiv 2020.03.07.981
- Weissman MR, Winger KT, Ghiassian S, Gobbo P, Workentin MS. Insights on the application of the retro michael-type addition on maleimide-functionalized gold nanoparticles in biology and nanomedicine. Bioconjug Chem. 2016;27(3):586–593.
- Dong L, Li C, Locuson C, Chen S, Qian MG. A two-step immunocapture LC/MS/MS assay for plasma stability and payload migration assessment of cysteine–maleimide-based antibody drug conjugates. Anal Chem. 2018;90(10):5989–5994.
- Liu W, Wang J, Wang S, Yue K, Hu Y, Liu X, Wang L, Wan S, Xu X. Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease. Bioorg Chem. 2023;140:106830.
- HyperChem(TM) Professional 7.51, Hypercube, Inc., 1115 NW 4th Street, Gainesville, Florida, USA. Available from: www.hyper.com.
- Hocquet A, Langgård M. An evaluation of the MM + force field. J Mol Model. (3)1998; 4:94–112.
- Trott O, Olson AJ. Autodock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. (2)2010; 31:455–461.
- Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. (1)1996; 14:33–38.
- Discovery Studio Visualizer, v20. 1. 0. p. 19295. San Diego: Dassault Systèmes.